ProfoundBio Stock

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Sign up today and learn more about ProfoundBio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About ProfoundBio Stock

ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.

Funding History

February 2021$10.0M
July 2021$55.0M
June 2022$70.0M
February 2024$112M


Chief Medical Officer

Naomi Hunder


Xiao Shang

Chief Scientific Officer

Zhu Chen

Founder & CEO

Baiteng Zhao


Tae H. Han

Member, Board of Directors

Andrew Lam

Board Member

Lynn Yang

Co-founder and Chief Strategy Officer

Tae Han


Erin Lavelle

CTO and Co-Founder

Xiao Shang

Board Member

Baiteng Zhao

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: